Dr Michael Morrison
Principal Investigator Biomodifying Technologies, HeLEX
Michael has an MA (by Research and Thesis) and PhD from the interdisciplinary Institute for Science and Society (ISS) at the University of Nottingham. He also holds a BSc in Biology from the University of St. Andrews (2000). Michael has previously worked on the IMI STEMBANCC project, providing governance and ethical support to the project. He has also been a researcher on the Framework Programme 7 Regenerative Medicine in Europe (REMEDiE) project at the University of York and with the Health Technology and Society group at the University of Exeter.
Michael’s primary research interest and expertise lies in the application of insights and perspectives from Science and Technology Studies (STS) and medical sociology to the study of novel and emerging biotechnologies. More specifically, he is concerned with understanding the ways in which these technologies are shaped by a variety of social factors – including institutional and regulatory cultures as well as the perspectives of developers and prospective users – throughout the course of their development and deployment into practice; and how, in turn, new biomedical technologies shape and reconfigure our understandings of disease, health, and the ‘sorts’ of people we are or can be. He is also working with Jane Kaye and other HeLEX members to develop novel consent procedures for large-scale biobanking projects.
The promises and challenges of biomodifying technologies for the UK
MORRISON M., (2019)
Reshaping the landscape of science and medicine
MORRISON M. et al, (2019)
Response to Open Peer Commentaries on "Patenting Foundational Technologies: Lessons From CRISPR and Other Core Biotechnologies".
Feeney O. et al, (2019), Am J Bioeth, 19, W10 - W13
Patenting Foundational Technologies: Lessons From CRISPR and Other Core Biotechnologies
Feeney O. et al, (2018), The American Journal of Bioethics, 18, 36 - 48
Valuing height: diagnosis, valuation and the case of idiopathic short stature.
Morrison M., (2018), Sociol Health Illn